Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital established a new position in Biohaven (BHVN), acquiring 513,184 shares valued at $5.79M at quarter-end, representing 2.6% of its reportable U.S. equity AUM. Biohaven shares traded at $8.90 (down ~70% over the past year), market cap ~$1.3B, TTM net loss ~$738.8M; company had ~$322M cash at end-2025 and raised an additional $178.9M after year-end. The stock is being added as a distressed, high-risk play after an FDA rejection of troriluzole and disappointing trial updates, while management narrows focus to a degrader platform and a Phase 2 obesity program (enrollment complete, data expected H2 2026).

Analysis

Sarissa’s entry should be read as a signal that specialist managers still find asymmetric value in single-asset, binary biotech risk despite sector-wide derating; that changes the marginal buyer/seller composition more than it moves headline market cap. The immediate second-order winners are acquirers and asset managers that can finance and integrate failed-or-reset programs — M&A optionality becomes the dominant implied upside on a stretched balance sheet, not routine commercial execution.

The next 3–12 months are pure catalyst-driven territory: readouts, partnering announcements, or a financed extension can re-price the asset by multiple turns, while any additional negative clinical news or unexpected dilution would compress value quickly. Market technicals amplify moves — low liquidity and concentrated holdings mean headline flow (insider selling, hedge fund exits, or a single block trade) can generate 20–40% intraday swings that bear no relation to fundamentals.

Consensus underestimates two offsets: (1) acquirers with deep therapeutic expertise may value specific programs materially higher than public markets if they can fold them into ongoing pipelines, and (2) CRO/outsourcer revenue streams tied to completing enrollment create a predictable near-term cash waterfall even if commercialization is distant. Conversely, consensus may be complacent on dilution timing; a single failed readout or missed milestone could trigger an equity raise that halves current equity value before any recovery is possible.

Key Decisions for Investors

• Tactical asymmetric long (BHVN): Allocate 0.5–1.0% of portfolio to long-dated calls (9–12 months) or a call spread to capture a successful mid‑/late-stage readout or asset sale; cap downside at premium paid and target 3–5x on a positive binary outcome. Exit/trim on 50–70% realized gain, or if clinical news delays beyond 12 months.
• Hedge the idiosyncratic bet: Pair the BHVN long with a short position in a liquid small‑cap biotech ETF or a basket of broadly exposed biotech names to neutralize sector beta (size the hedge to leave ~70% idiosyncratic exposure). This isolates trial/M&A risk while limiting drawdowns from broad biotech selloffs within 3 months.
• Defensive reallocation (NBIX, CYTK): Reduce broad biotech beta and rotate 1–2% into higher-quality or revenue‑adjacent biotech (e.g., NBIX or CYTK analogues) with longer-duration optionality and less binary clinical risk; expect lower upside but <1/3 the binary downside over 6–12 months.
• Event-driven short/vol play: If a headline-driven pop (>20% intraday) occurs without new clinical or financing clarity, sell short-dated calls or establish a small short position with tight stops to harvest volatility premium — target a 20–30% return on risk if sentiment mean-reverts within 2–6 weeks.